Blood product transfusions are associated with an increase in serum (1-3)-beta-d-glucan in infants during the initial hospitalization in neonatal intensive care unit (NICU)

Abstract

Introduction: Serum (1-3)-beta-d-glucan (BDG) assay has been proposed as an adjunct for the rapid diagnosis of invasive fungal infection (IFI). However, false-positive results have been reported following transfusion of blood products in adults.

Aims: To assess the relationship between blood product transfusion and elevated BDG in neonates.

Method: Retrospective study including neonates ≤32 weeks, with no fungal colonization or infection, in whom BDG assay was performed for suspicion of IFI. Patients were classified in Transfusion (n = 78) and No Transfusion (n = 55) groups depending on whether or not they were transfused. Clinical, biochemical and microbiological characteristics were recorded. A BDG assay >80 pg/mL was considered as positive. Statistical analyses: bivariate and multivariate logistic regression.

Results (median, IQR): One hundred and thirty-three infants were included (gestational age 28.4 weeks, 26.9–30; birth weight 1000 g, 847–1300). BDG was higher in the Transfusion group (170 pg/mL, 65–317) than in the No Transfusion group (57 pg/mL, 34–108; p < 0.001). False-positive BDG assay results were associated with red blood cells (RBC) and fresh frozen plasma (FFP) transfusions.

Conclusion: BDG is increased after RBC and FFP transfusions in neonates, leading to overdiagnosis of IFI. Fungal colonization status in peripheral sites and central cultures could help to reduce the risk of misdiagnosis.

Keywords:

• Beta-d-glucan
• biomarker
• neonatal candidiasis
• neonatal infection
• NICU

Declaration of interest

The authors report no declarations of interest.